Anti-ganglioside antibody and neuropathy: Review of our research

Journal of the Peripheral Nervous System

Volumn 3, Issue 1, 1998, Pages 3-18

  Yuki, Nobuhiro ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti ganglioside antibody; Anti GM1 antibody; Anti GQ1b antibody; Autoimmune; Bickerstaff's brainstem encephalitis; Camphylobacter jejuni; Fisher's syndrome; Guillain Barre syndrome; Lipopolysaccharide; Molecular mimicry

Indexed keywords

GANGLIOSIDE ANTIBODY;

AMYOTROPHIC LATERAL SCLEROSIS; CAMPYLOBACTER JEJUNI; HUMAN; MUSCLE WEAKNESS; NERVE FIBER DEGENERATION; NEUROTOXICITY; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW;

ANTIBODIES; ATAXIA; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; DEMYELINATING DISEASES; ENTERITIS; GANGLIOSIDES; GUILLAIN-BARRE SYNDROME; HUMANS; MILLER FISHER SYNDROME; NERVOUS SYSTEM DISEASES;

EID: 0031931531     PISSN: 10859489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AD, Koopman WF, Zochodne DW: An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986;109:1115-1126.
2. Freddo L, Yu RK, Latov N, Donofrio PD, Hays AP, Greenberg HS, Albers JW, Allessi AG, Keren D: Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease. Neurology 1986; 36:454-458.
3. Ilyas AA, Willison HJ, Quarles RH, Jungalwala FB, Cornblath DR, Trapp BD, Griffin DE, Griffin JW, McKhann GM: Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann. Neurol. 1988; 23:440-447.
4. Inuzuka T, Miyatani N, Baba H, Tanaka M, Tanaka K, Sato S, Nakamura K, Miyatake T: IgM binding to sialosyllactosaminylparagloboside in a patient with polyradiculoneuropathy due to Mycoplasma pneumoniae infection. Acta Neurol. Scand. 1988; 78:53-57.
5. Kaldor J, Speed BR: Guillain-Barré syndrome and Campylobacter jejuni: A serological study. Br. Med. J. 1984; 288:1867-1870.
6. Yuki N, Yoshino H, Sato S, Miyatake T: Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990; 40:1900-1902.
7. Enders U, Karch H, Toyka KV, Michels M, Zielasek J, Pette M, Heesemann J, Hartung H-P: The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann. Neurol. 1993; 34:136-144.
8. Vriesendorp FJ, Mishu B, Blaser MJ, Koski CL: Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: Correlation and prognosis. Ann. Neurol. 1993; 34:130-135.
9. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM: Guillain-Barré syndrome in northern China: Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995; 118:597-605.
10. Kornberg AJ, Pestronk A, Bieser K, Ho TW, McKhann GM, Wu HS, Jiang Z: The clinical correlates of hightiter IgG anti-GM1 antibodies. Ann. Neurol. 1994; 35:234-237.
11. Rees JH, Gregson NA, Hughes RAC: Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann. Neurol. 1995; 38:809-816.
12. Visser LH, van der Meché FGA, van Doom PA, Meulstee J, Jacobs BC, Oomes PG, Kleyweg RP, the Dutch Guillain-Barré Study Group: Guillain-Barré syndrome without sensory loss (acute motor neuropathy): A subgroup with specific clinical, electrodiagnostic and laboratory features. Brain 1995; 118:841-847.
13. Jacobs BC, van Doom PA, Schmitz PIM, Tio-Gillen AP, Herbrink P, Visser LH, Hooijkaas H, van der Meché FGA: Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann. Neurol. 1996; 40:181-187.
14. Yuki N, Yoshino H, Sato S, Shinozawa K, Miyatake T: Severe acute axonal form of Guillain-Barré syndrome associaled wilh IgG anti-GD1a anlibodies. Muscle Nerve 1992; 15:899-903.
15. Yuki N, Yamada M, Sato S, Ohama E, Kawase Y, Ikuta F, Miyatake T: Association of IgG anti-GD1a antibody wilh severe Guillain-Barré syndrome. Muscle Nerve 1993; 16:642-647.
16. Carpo M, Nobile-Orazio E, Meucci N, Gamba M, Barbieri S, Allaria S, Scarlato G: Anti-GD1a ganglioside antibodies in peripheral motor syndromes. Ann. Neurol. 1996; 39:539-543.
17. Triggs WJ, Cros D: Axonal Guillain-Barré syndrome. Neurology 1993; 43:1443-1444.
18. Cros D, Triggs WJ: There are no neurophysiologic features characteristic of "axonal" Guillain-Barré syndrome. Muscle Nerve 1994; 17:675-677.
19. Yuki N, Miyatake T: Axonal Guillain-Barré syndrome: reply. Neurology 1993; 43:1443-1444.
20. Yuki N: Pathogenesis of axonal Guillain-Barré syndrome: Hypothesis. Muscle Nerve 1994; 17:680-682.
21. McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, Wu HS, Zhaori G, Liu Y, Jou LP, Liu TC, Gao CY, Mao JY, Blaser MJ, Mishu B, Asbury AK: Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China. Ann. Neurol. 1993; 33:333-342.
22. Griffin JW, Li CY, Ho TW, Xue P, Macko C, Gao CY, Yang C, Tian M, Mishu B, Cornblath DR, McKhann GM, Asbury AK: Guillain-Barré syndrome in northern China: The spectrum of neuropathological changes in clinically defined cases. Brain 1995; 118: 577-595.
23. Griffin JW, Li CY, Macko C, Ho TW, Hsieh S-T, Xue P, Wang FA, Cornblath DR, MaKhann GM, Asbury AK: Early nodal change in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J. Neurocytol. 1996; 25:33-51.
24. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, Mishu B, Cornblath DR, Macko C, McKhann GM, Asbury AK: Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann. Neurol. 1996; 39:17-28.
25. Hafer-Macko C, Hsieh S-T, Li CY, Ho TW, Sheikh K, Cornblath DR, McKhann GM, Asbury AK, Griffin JW: Acute motor axonal neuropathy: An antibody-mediated attack on axolemma. Ann. Neurol. 1996; 40:635-644.
26. Yuki N, Sato S, Miyatake T, Sugiyama K, Katagiri T, Sasaki H: Motoneuron-disease-like disorder after ganglioside therapy. Lancet 1991; 337:1109-1110.
27. Yuki N, Sato S, Miyatake T, Sugiyama K, Katagiri T, Sasaki H: Motoneuron-disease-like disorder after ganglioside therapy: reply. Lancet 1991; 338:314-315.
28. Yuki N, Miyatake T, Ichihashi Y, Sato S, Katagiri T: IgM anti-(Ga1NAc β1-4 Gal [3-2α NeuAc] β1-) antibody-mediated cytotoxicity in a patient with amyotrophic lateral sclerosis-like disorder. Muscle Nerve 1992; 15:1371-1373.
29. Nakao T, Kon K, Ando S, Miyatake T, Yuki N, Li Y-T, Furuya S, Hirabayashi Y: Novel lacto-ganglio type gangliosides with GM2-epitope in bovine brain which react with IgM from a patient of the amyotrophic lateral sclerosis-like disorder. J. Biol. Chem. 1993; 268:21028-21034.
30. Matsumoto A, Yoshino H, Yuki N, Hara Y, Cashman NR, Handa S, Miyatake T: Ganglioside characterization of a cell line displaying motor neuron-like phenotype: GM2 as a possible major ganglioside in motor neurons. J. Neurol. Sci. 1995; 131:111-118.
31. Mitsumoto H, Sliman RJ, Schafer IA, Sternick CS, Kaufman B, Wilbourn A, Horwitz SJ: Motor neuron disease and adult hexosaminidase A deficiency in two families: Evidence for multisystem degeneration. Ann. Neurol. 1985; 17:378-385.
32. Cashman NR, Antel JP, Hancock LW, Dawson G, Horwitz AL, Johnson WG, Huttenlochter PR, Wollmann RL: N-acetyl-β-hexosaminidase β locus defect and juvenile motor neuron disease: A case study. Ann. Neurol. 1986; 19:568-572.
33. Saleh MN, Khazaeli MB, Wheeler R, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russel CH, LoBuglio AF: Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res. 1992; 52:4342-4347.
34. Yuki N, Yamada M, Tagawa Y, Takahashi H, Handa S: Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy. J. Neurol. Sci. 1997; 149:127-130.
35. Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, Reisfeld RA: Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 1989; 49:2857-2861.
36. Berlit P: Cronassial. Tägl. Praxis 1989; 30:358-360.
37. Latov N, Koski CL, Walicke PA: Guillain-Barré syndrome and parenteral ganglioside. Lancet 1991; 338:757.
38. Schönhöfer PS: Guillain-Barré syndrome and parenteral ganglioside. Lancet 1991; 338:757.
39. Figueras A, Morales-Olivas FJ, Capellà D, Palop V, Laporte J-R: Bovine gangliosides and acute motor polyneuropathy. Br. Med. J. 1992; 305:1330-1331.
40. Nobile-Orazio E, Carpo M, Meucci N, Grassi MP, Capitani E, Sciacco M, Mangoni A, Scarlato G: Guillain-Barré syndrome associated with high titers of anti-GM1 antibodies. J. Neurol. Sci. 1992; 109:200-206.
41. Landi G, D'Alessandro R, Dossi BC, Ricci S, Simone IL, Ciccone A: Guillain-Barré syndrome after exogeneous gangliosides in Italy. Br. Med. J. 1993; 307: 1463-1464.
42. Illa I, Ortiz N, Gallard E, Juarez C, Grau JM, Dalakas MC: Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann. Neurol. 1995; 38:218-224.
43. Kuroki S, Saida T, Nukina M, Haruta T, Yoshioka M, Kobayashi Y, Nakanishi H: Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain β-N-acetylglucosamine residues. Ann. Neurol. 1993; 33:243-247.
44. Yuki N, Sato S, Fujimoto S, Yamada S, Tsujino Y, Kinoshita A, Itoh T: Serotype of Campylobacter jejuni, HLA, and the Guillain-Barré syndrome. Muscle Nerve 1992; 15:968-969.
45. Yuki N, Handa S, Taki T, Kasama T, Takahashi M, Saito K, Miyatake T: Cross-reactive antigen between nervous tissue and a bacterium elicits Guillain-Barré syndrome: molecular mimicry between ganglioside GM1 and lipopolysaccharide from Penner's serotype 19 of Campylobacter jejuni. Biomed. Res. 1992; 13:451-453.
46. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T: A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J. Exp. Med. 1993; 178:1771-1775.
47. Wirguin I, Suturkova-Milosevic L, Della-Latta P, Fisher T, Brown RH Jr, Latov N: Monoclonal IgM antibodies to GM1 and asialo-GM1 in chronic neuropathies cross-react with Campylobacter jejuni lipopolysaccharides. Ann. Neurol. 1994; 35:698-703.
48. Oomes PG, Jacobs BC, Hazenberg MPH, Bänffer JRJ, van der Meché FGA: Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: Evidence of molecular mimicry. Ann. Neurol. 1995; 38:170-175.
49. Willison HJ, Veitch J: Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J. Neuroimmunol. 1994; 50:159-165.
50. Yuki N, Ichihashi Y, Taki T: Subclass of IgG antibody to GM1 epitope-bearing lipopolysaccharide of Campylobacter jejuni in patients with Guillain-Barré syndrome. J. Neuroimmunol. 1995; 60:161-164.
51. Aspinall GO, McDonald AG, Raju TS, Pang H, Moran AP, Penner JL: Chemical structures of the core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides. Eur. J. Biochem. 1993; 213:1017-1027.
52. Yuki N, Taki T, Takahashi M, Saito K, Tai T, Miyatake T, Handa S: Penner's serotype 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1a epitope. Infect. Immun. 1994; 62:2101-2103.
53. Aspinall GO, McDonald AG, Pang H, Kurjanczyk LA, Penner JL: Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 1994; 33:241-249.
54. Yuki N, Tsujino Y: Familial Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis. J. Pediatr. 1995; 126:162.
55. Yuki N, Handa S, Tai T, Takahashi M, Saito K, Tsujino Y, Taki T: Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (PEN 19) in three isolates from patients with Guillain-Barré syndrome. J. Neurol. Sci. 1995; 130:112-116.
56. Yuki N, Takahashi M, Tagawa Y, Kashiwase K, Tadokoro K, Saito K: Association of Campylobacter jejuni serotype with anti-ganglioside antibody in Guillain-Barré syndrome. Ann. Neurol. 1997; 42:28-33.
57. Aspinall GO, McDonald AG, Pang H: Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of O antigen chains from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 1994; 33:250-255.
58. Schluep M, Steck AJ: Immunostaining of motor nerve terminals by IgM M protein with activity against gangliosides GM1 and GD1b from a patient with motor neuron disease. Neurology 1988; 38:1890-1892.
59. Corbo M, Quattrini A, Latov N, Hays A: Localization of GM1 and Gal(β1-3)GalNAc antigenic determinants in peripheral nerve. Neurology 1993; 43:809-814.
60. Thomas FP, Trojaborg W, Nagy C, Santoro M, Sadiq SA, Latov N, Hays AP: Experimental autoimmune neuropathy with anti-GM1 antibodies and immunoglobulin deposits at the nodes of Ranvier. Acta Neuropathol. 1991; 82:378-383.
61. Santoro M, Uncini A, Corbo M, Staugaitis SM, Thomas FP, Hays AP, Latov N: Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann. Neurol. 1992; 31:385-390.
62. Uncini A, Santoro M, Corbo M, Lugaresi A, Latov N: Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve 1993; 16:610-615.
63. Arasaki K, Kusunoki S, Kudo N, Kanazawa I: Acute conduction block in vitro following exposure to anti-ganglioside sera. Muscle Nerve 1993; 16:587-593.
64. Roberts M, Willison HJ, Vincent A, Newsom-Davis J: Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann. Neurol. 1995; 37:436-442.
65. + currents in isolated rat myelinated nerve fibers. Ann. Neurol. 1995; 37:436-442.
66. Kobayashi T, Michikawa M, Park-Matsumoto YC, Kameda N, Yuki N, Miyatake T: Inhibition of motor neuron excitability by serum with anti-GM1 & GM2 antibodies and their monoclonal ones. Can. J. Neurol. Sci. 1993; 20(suppl. 4):S134. [abstract]
67. Apostolski S, Sadiq SA, Hays A, Corbo M, Suturkova-Milosevic L, Chaliff P, Stefansson K, LeBaron RG, Ruoslahti E, Hays AP, Latov N: Identification of Gal(β1-3)GalNAc bearing glycoproteins at the nodes of Ranvier in peripheral nerve. J. Neurosci. Res. 1994; 38:134-141.
68. Yuki N, Sato S, Yoshino H, Miyatake T: Axonal Guillain-Barré: reply. Neurology 1991;41:1530-1531.
69. Yuki N, Yoshino H, Sato S, Miyatake T: Campylobacter neuropathy: reply. Neurology 1991; 41:1327-1328.
70. van der Meché FGA, Schmitz PIM, the Dutch Guillain-Barré Study Group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N. Engl. J. Med. 1992; 326:1123-1129.
71. Yuki N, Miyagi F: Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies. J. Neurol. Sci. 1996; 139:160-162.
72. Malik U, Oleksowicz L, Latov N, Cardo LJ: Intravenous γ-globulin inhibits binding of anti-GM1 to its target antigen. Ann. Neurol. 1996; 39:136-139.
73. Kusunoki S, Chiba A, Kon K, Ando S, Arisawa K, Tate A, Kanazawa I: N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann. Neurol. 1994; 35:570-576.
74. Yuki N, Taki T, Handa S: Antibody to GalNAc-GD1a and GalNAc-GM1b in Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis. J. Neuroimmunol. 1996; 71:155-161.
75. Hirabayashi Y, Hyogo A, Nakao T, Tsuchiya K, Suzuki Y, Matsumoto M, Kon Kon Ando S: Isolation and characterization of extremely minor gangliosides, GM1b and GD1α, in adult bovine brains as developmentally regulated antigens. J. Biol. Chem. 1990; 265: 8144-8151.
76. Kusunoki S, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I: GM1b is a new member of antigen for serum antibody in Guillain-Barré syndrome. Neurology 1996; 47:237-242.
77. Yuki N, Tagawa Y, Irie F, Hirabayashi Y, Handa S: Close association of Guillain-Barré syndrome with antibodies to minor monosialogangliosides GM1b and GM1α. J. Neuroimmunol. 1997;74:30-34.
78. Svennerholm L, Boström K, Fredman P, Jungbjer B, Lekman A, Månsson J-E, Rynmark B-M: Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim. Biophys. Acta 1994; 1214:115-123.
79. Yuki N, Tagawa Y, Handa S: Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG, and SGPG in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1996; 70:1-6.
80. Irie S, Saito T, Nakamura K, Kanazawa N, Ogino M, Nukazawa T, Ito H, Tamai Y, Kowa H: Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. J. Neuroimmunol. 1996; 68:19-26.
81. Yuki N, Tagawa Y, Handa S: Molecular mimicry between cytomegalovirus and GM2 ganglioside: Pathogenesis of Guillain-Barré syndrome. Ann. Neurol. 1996; 40:519. [abstract]
82. Chiba A, Kusunoki S, Shimizu T, Kanazawa I: Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann. Neurol. 1992; 31:677-679.
83. Willison HJ, Veitch J, Paterson G, Kennedy PGE: Miller Fisher syndrome is associated with antibodies to GQ1b ganglioside. J. Neurol. Neurosurg. Psychiatry 1993; 56:204-206.
84. Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T: Frequent presence of anti-GQ1b antibody in Fisher's syndrome. Neurology 1993; 43:414-417.
85. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I: Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome:Clinical and immunohistochemical studies. Neurology 1993; 43:1911-1917.
86. Nagaoka U, Kato T, Kurita K, Arawaka S, Hosoya T, Yuki N, Shikama Y, Yamaguchi K, Sasaki H: Cranial nerve enhancement on three-dimensional MRI in Miller Fisher syndrome. Neurology 1996; 47:1601-1602.
87. Takano H, Yuki N: Fisher's syndrome associated with chickenpox and anti-GQ1b antibody. J. Neurol. 1995; 242:255-256.
88. Yuki N, Ichikawa H, Doi A: Fisher syndrome after Campylobacter jejuni enteritis: Human leukocyte antigen and the bacterial serotype. J. Pediatr. 1995; 126:55-57.
89. Yuki N, Taki T, Takahashi M, Saito K, Yoshino H, Tai T, Handa S, Miyatake T: Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann. Neurol. 1994; 36:791-793.
90. Jacobs BC, Endtz HPh, van der Meché FGA, Hazenberg MP, Achtereekte HAM, van Doom PA: Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann. Neurol. 1995; 37:260-264.
91. Bickerstaff ER, Cloake PCP: Mesencephalitis and rhombencephalitis. Br. Med. J. 1951;2:77-81.
92. Bickerstaff ER: Brain-stem encephalitis: further observations on a grave syndrome with benign prognosis. Br. Med. J. 1957; 1:1384-1387.
93. Yuki N, Sato S, Tsuji S, Hozumi I, Miyatake T: An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J. Neurol. Sci. 1993; 118:83-87.
94. Yuki N, Wakabayashi K, Yamada M, Seki K: Overlap of Guillain-Barré syndrome and Bickerstaff's brainstem encephalitis. J. Neurol. Sci. 1997; 145:119-122.
95. Yuki N: Successful plasmapheresis in Bickerstaff's brain stem encephalitis associated with anti-GQ1b antibody. J. Neurol. Sci. 1995; 131:108-110.
96. Yuki N: Acute paresis of extraocular muscles associated with IgG anti-GQ1b antibody. Ann. Neurol. 1996; 39:668-672.
97. Irvine AT, Tibbles J: Treatment of Fisher's variant of Guillain-Barré syndrome by exchange transfusion. Can. J. Neurol. Sci. 1981; 8:49-50.
98. Littlewood R, Bajada S: Successful plasmapheresis in the Miller-Fisher syndrome. Br. Med. J. 1981; 282:778.
99. Yuki N, Miyatake T, Ohsawa T: Beneficial effect of plasmapheresis on Fisher's syndrome. Muscle Nerve 1993; 16:1267-1268.
100. Yuki N: Tryptophan-immobilized column adsorbs immunoglobulin G anti-GQ1b antibody from Fisher's syndrome: A new approach to treatment. Neurology 1996; 46:1644-1651.
101. Guillain-Barré Study Group: Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35:1096-1104.
102. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome: Efficiency of plasma exchange in Guillain-Barré syndrome: Role of replacement fluids. Ann. Neurol. 1987; 22:753-761.
103. Yuki N: Fisher's syndrome: reply. Neurology 1994; 44:360.
104. Windebank AJ, Blexrud MD, Dyck PJ, Daube JR, Karnes JL: The syndrome of acute sensory neuropathy: Clinical features and electrophysiologic and pathologic changes. Neurology 1990; 40:584-591.
105. Yuki N, Miyatani N, Sato S, Hirabayashi Y, Yamazaki M, Yoshimura N, Hayashi Y, Miyatake T: Acute relapsing sensory neuropathy associated with IgM antibody against B-series gangliosides containing a GalNAc β1-4 Gal(3-2α NeuAc 8-2α NeuAc)β1 configuration. Neurology 1992; 42:686-689.
106. Ohsawa T: Rat dorsal root ganglion gangliosides during early development until senescence. Mech. Ageing Dev. 1990; 53:259-266.
107. Ohsawa T, Miyatake T, Yuki N: Anti-B-series ganglioside-recognizing autoantibodies in an acute sensory neuropathy patient cause cell death of rat dorsal root ganglion neurons. Neurosci. Lett. 1993; 157:167-170.
108. Ilyas AA, Quarles RH, Dalakas MC, Fishman PH, Brady RO: Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups. Ann. Neurol. 1985; 18:655-659.
109. 2 IgMκ M proteinemia. J. Neurol. 1992; 239:147-151.
110. Daune GC, Farrer RG, Dalakas MC, Quarles RH: Sensory neuropathy associated with monoclonal immunoglobulin M to GD1b ganglioside. Ann. Neurol. 1992; 31:683-685.
111. Obi T, Kusunoki S, Takatsu M, Mizoguchi K, Nishimura Y: IgM M-protein in a patient with sensory-dominant neuropathy binds preferentially to polysialogangliosides. Acta Neurol. Scand. 1992; 86:215-218.
112. 2 cold agglutinins. J. Neurol. Nenrosurg. Psychiatry 1993; 56:1178-1183.
113. 1d specificity in a patient with peripheral neuropathy. Vox Sang. 1994; 67:58-63.
114. Oka N, Kusaka H, Kusunoki S, Tsuda H, Kaji R, Imai T, Akiguchi I, Kimura J: IgM M-protein with antibody activity against gangliosides with disialosyl residue in sensory neuropathy binds to sensory neurons. Muscle Nerve 1996; 19:528-530.
115. Hirabayashi Y, Nakao T, Irie F, Whittaker VP, Kon K, Ando S: Structural characterization of a novel cholinergic neuron-specific ganglioside in bovine brain. J. Biol. Chem. 1992; 267:12973-12978.
116. Tagawa Y, Irie F, Hirabayashi Y, Yuki N: Cholinergic neuron-specific ganglioside GQ1bα a possible target molecule for serum IgM antibodies in some patients with sensory ataxia. J. Neuroimmunol. 1997; 75:196-199.
117. Kusunoki S, Chiba A, Hirabayashi Y, Irie F, Kotani M, Kawashima I, Tai T, Nagai Y: Generation of a monoclonal antibody specific for a new class of minor ganglioside antigens, GQ1bα and GT1aα: Its binding to dorsal and lateral horn of human thoracic cord. Brain Res. 1993; 623:83-88.